Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PGEN | Common Stock | Options Exercise | +9.77K | +1.36% | 727K | Jan 2, 2022 | Direct | F1 | ||
transaction | PGEN | Common Stock | Sale | -$14.1K | -3.85K | -0.53% | $3.67 | 723K | Jan 3, 2022 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PGEN | Restricted Stock Units | Options Exercise | $0 | -9.77K | -100% | $0.00* | 0 | Jan 2, 2022 | Common Stock | 9.77K | Direct | F1, F3 |
Id | Content |
---|---|
F1 | Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. |
F2 | This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. |
F3 | The RSUs were granted on January 2, 2018 and have vested in full. |